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Special Contribution
Update of the Drug Resistance Mutations in HIV-1:  
December 2010
Victoria A. Johnson, MD, Françoise Brun-Vézinet, MD, PhD, Bonaventura Clotet, MD, PhD, 
Huldrych F. Günthard, MD, Daniel R. Kuritzkes, MD, Deenan Pillay, MD, PhD, Jonathan M. 
Schapiro, MD, and Douglas D. Richman, MD
This December 2010 version of the 
International AIDS Society–USA (IAS–
USA) drug resistance mutations list 
updates the figures last published in 
December 2009 (Johnson VA et al, 
Top HIV Med, 2009;17:138-145). This 
update includes 9 new mutations—
E138G and E138K for etravirine (Had-
dad M et al, CROI, 2010; Abstract 574, 
and Vingerhoets J et al, Antivir Ther, 
2010;15 [Suppl 2]:A125); E92Q for 
raltegravir (Geretti AM et al, Antivir 
Ther, 2010;15 [Suppl 2]:A62; Cooper 
et al, N Engl J Med, 2008;359:355-365; 
and Malet I et al, Antimicrob Agents 
Chemother, 2008;52:1351-1358); and 
M36L, M36V, H69R, L89I, L89M, and 
L89V for tipranavir/ritonavir. In ad-
dition, the tipranavir/ritonavir N83D 
mutation designation was changed 
to boldface to indicate its recognition 
as a major mutation rather than a mi-
nor mutation. The mutations I13V, 
K20M/R, E35G, and L90M were re-
moved from the tipranavir/ritonavir 
bar, reflecting new understanding. 
For etravirine, L100I*, K101P*, and 
Y181C*/I*/V* are denoted with as-
terisks (instead of bolded) to reflect 
that these individual mutations each 
have the greatest impact (ie, highest 
weighting scores) on reduced pheno-
typic susceptibility and impaired clini-
cal response when compared with 
other etravirine mutations (Haddad 
M et al, CROI, 2010; Abstract 574). In 
addition, user notes d, n, r, w, and z 
were revised.
Methods
Mutations Panel 
The authors comprise the IAS–USA 
Drug Resistance Mutations Group, an 
independent, volunteer panel of experts 
charged with the goal of delivering ac-
curate, unbiased, and evidence-based 
information on these mutations to HIV 
clinical practitioners. The group re-
views new data on HIV drug resistance 
to maintain a current list of mutations 
associated with clinical resistance to 
HIV. This list includes mutations that 
may contribute to a reduced virologic 
response to a drug.
In addition, the group reviews only 
data that have been published or have 
been presented at a scientific confer-
ence. Drugs that have been approved 
by the US Food and Drug Administra-
tion (US FDA) as well as any drugs avail-
able in expanded access programs are 
included (listed in alphabetical order 
by drug class). User notes provide ad-
ditional information as necessary. Al-
though the Drug Resistance Mutations 
Group works to maintain a complete 
and current list of these mutations, it 
cannot be assumed that the list pre-
sented here is exhaustive.
Identification of Mutations 
The mutations listed have been identi-
fied by 1 or more of the following crite-
ria: (1) in vitro passage experiments or 
validation of contribution to resistance 
by using site-directed mutagenesis; (2) 
susceptibility testing of laboratory or 
clinical isolates; (3) nucleotide sequenc-
ing of viruses from patients in whom the 
drug is failing; (4) correlation studies be-
tween genotype at baseline and virologic 
response in patients exposed to a drug.
The development of more recently 
approved drugs that cannot be tested 
as monotherapy precludes assess-
ment of the impact of resistance on 
antiretroviral activity that is not seri-
ously confounded by activity of other 
drug components in the background 
regimen. Readers are encouraged to 
consult the literature and experts in 
the field for clarification or more infor-
mation about specific mutations and 
their clinical impact. Polymorphisms 
associated with impaired treatment re-
sponses that occur in wild-type viruses 
should not be used in epidemiologic 
analyses to identify transmitted HIV-1 
drug resistance.
Clinical Context
The figures are designed for practitio-
ners to use in identifying key muta-
tions associated with viral resistance 
to antiretroviral drugs and in making 
therapeutic decisions. In the context 
of making clinical decisions regarding 
antiretroviral therapy, evaluating the 
results of HIV-1 genotypic testing in-
cludes: (1) assessing whether the pat-
tern or absence of a pattern in the mu-
tations is consistent with the patient’s 
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antiretroviral therapy history; (2) rec-
ognizing that in the absence of drug 
(selection pressure), resistant strains 
may be present at levels below the 
limit of detection of the test (analyzing 
stored samples, collected under selec-
tion pressure, could be useful in this 
setting); and (3) recognizing that viro-
logic failure of the first regimen typi-
cally involves HIV-1 isolates with resis-
tance to only 1 or 2 of the drugs in the 
regimen (in this setting, resistance de-
velops most commonly to lamivudine 
or the nonnucleoside analogue reverse 
transcriptase inhibitors [NNRTIs]).
The absence of detectable viral re-
sistance after treatment failure may 
result from any combination of the 
following factors: the presence of drug-
resistant minority viral populations, 
nonadherence to medications, labora-
tory error, lack of current knowledge 
of the association of certain mutations 
with drug resistance, the occurrence of 
relevant mutations outside the regions 
targeted by routine resistance assays, 
drug-drug interactions leading to sub-
therapeutic drug levels, and possibly 
compartmental issues, indicating that 
drugs may not reach optimal levels in 
specific cellular or tissue reservoirs.
For more in-depth reading and an 
extensive reference list, see the 2008 
IAS–USA panel recommendations for 
resistance testing (Hirsch MS et al, Clin 
Infect Dis, 2008;47:266-285) and 2010 
IAS–USA panel recommendations for 
antiretroviral therapy (Thompson MA 
et al, JAMA, 2010;304[3]:321-333). Up-
dates are posted periodically at www.
iasusa.org.
Comments
Please send your evidence-based 
comments, including relevant ref-
erence citations, to the IAS–USA at 
resistance2011“at”iasusa.org or by 
fax at 415-544-9401. Please include 
your name and institution.
Reprint Requests
The Drug Resistance Mutations Group 
welcomes interest in the mutations 
figures as an educational resource for 
practitioners and encourages dissemi-
nation of the material to as broad an 
audience as possible. However, per-
mission is required to reprint the fig-
ures and no alterations in the con-
tent can be made.
Requests to reprint the material 
should include the name of the pub-
lisher or sponsor, the name or a de-
scription of the publication in which 
you wish to reprint the material, the 
funding organization(s), if applicable, 
and the intended audience of the publi-
cation. Requests to make any minimal 
adaptations of the material should in-
clude the former, plus a detailed expla-
nation of how the adapted version will 
be changed from the original version 
and, if possible, a copy of the proposed 
adaptation. To ensure the integrity of 
the mutations figures, IAS–USA policy 
is to grant permission for only minor, 
preapproved adaptations of the figures 
(eg, an adjustment in size). Minimal 
adaptations only will be considered; 
no alterations of the content of the fig-
ures or user notes will be permitted. 
Please note that permission will be 
granted only for requests to reprint or 
adapt the most current version of the 
mutations figures as they are posted 
on the Web site (www.iasusa.org). 
Because scientific understanding of 
HIV drug resistance evolves rapidly 
and the goal of the Drug Resistance 
Mutations Group is to maintain the 
most up-to-date compilation of muta-
tions for HIV clinicians and research-
ers, publication of out-of-date figures 
is counterproductive. If you have any 
questions about reprints or adapta-
tions, please contact us. 
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MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE ASSOCIATED WITH RESISTANCE TO REVERSE TRANSCRIPTASE INHIBITORS
Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (nRTIs)a
Nonnucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs)a,m
Multi-nRTI Resistance: 69 Insertion Complexb (affects all nRTIs currently approved by the US FDA)
Multi-nRTI Resistance: 151 Complexc (affects all nRTIs currently approved by the US FDA except tenofovir)
Multi-nRTI Resistance: Thymidine Analogue-Associated Mutationsd,e (TAMs; affect all nRTIs currently approved 
by the US FDA)
Abacavirf,g
Didanosineg,h
Emtricitabine
Lamivudine
Stavudined,e,g,i,j,k
Tenofovirl
Zidovudined,e,j,k
Etravirinen
Efavirenz
Nevirapine
M
41
L
M
41
L
D
67
N
K
65
R
L
74
V
K
65
R
K
65
R
K
65
R
K
65
R
K
65
R
L
74
V
Y
115
F
M
184
V
M
184
V
I
M
184
V
I
A
62
V
A
62
V
V
75
I
F
77
L
F
116
Y
Q
151
M
K
70
R
K
70
R
M
41
L
D
67
N
K
70
R
K
70
E
M
41
L
D
67
N
K
70
R
L
210
W
T
215
Y
F
K
219
Q
E
L
210
W
T
215
Y
F
K
219
Q
E
L
210
W
T
215
Y
F
V
106
I
E
138
A
G
K
K
103
N
V
106
M
V
108
I
G
190
S
A
G
190
S
A
M
230
L
L
100
I
L
100
  I*
A
98
G
V
90
I
Y
181
C
I
Y
188
L
K
103
N
V
106
A
M
V
108
I
G
190
A
L
100
I
Y
181
C
I
Y
188
C
L
H
P
225
H
K
219
Q
E
L
210
W
T
215
Y
F
K
219
Q
E

69
Insert
Y
181
   C*   I*   V*
V
179
D
F
T
K
101
E
H
  P*
K
101
P
K
101
P
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MUTATIONS IN THE PROTEASE GENE ASSOCIATED WITH RESISTANCE TO PROTEASE INHIBITORSo,p,q
Atazanavir
+/– ritonavirr
Fosamprenavir/
ritonavir
Darunavir/
ritonavirs
Indinavir/
ritonavirt
Lopinavir/
ritonaviru
Nelfinavirt,v
Saquinavir/
ritonavirt
Tipranavir/
ritonavirw
L
10
I
F
V
C
G
16
E
K
20
R
M
I
T
V
L
24
I
V
32
I
L
33
I
F
V
L
33
F
E
34
Q
M
36
I
L
V
M
46
I
L
G
48
V
F
53
L
Y
D
60
E
I
62
V
I
54
L
V
M
T
A
I
64
L
M
V
A
71
V
I
T
L
G
73
C
S
T
A
V
82
A
T
F
I
I
93
L
M
I
85
V
L
90
M
I
84
V
L
10
V
L
33
F
M
36
I
L
V
M
46
L
I
47
V
K
43
T
I
54
A
M
V
L
89
I
M
V
Q
58
E
H
69
K
R
T
74
P
V
82
L
T
N
83
D
I
84
V
L
10
I
R
V
L
24
I
G
48
V
I
62
V
I
54
V
L
A
71
V
T
G
73
S
V
77
I
V
82
A
F
T
S
L
90
M
I
84
V
N
88
S
L
10
F
I
D
30
N
M
36
I
M
46
I
L
A
71
V
T
V
77
I
V
82
A
F
T
S
L
90
M
I
84
V
N
88
D
S
I
50
L
L
10
F
I
R
V
K
20
M
R
L
24
I
V
32
I
L
33
F
M
46
I
L
I
47
V
A
F
53
L
I
54
V
L
A
M
T
S
L
63
P
A
71
V
T
G
73
S
V
82
A
F
T
S
L
90
M
I
84
V
I
50
V
L
10
I
R
V
K
20
M
R
L
24
I
V
32
I
M
36
I
M
46
I
L
I
54
V
A
71
V
T
G
73
S
A
V
77
I
V
82
A
F
T
L
90
M
I
84
V
L
10
F
I
R
V
V
32
I
M
46
I
L
I
47
V
I
54
L
V
M
G
73
S
V
82
A
F
S
T
L
90
M
I
84
V
I
50
V
V
11
I
V
32
I
I
47
V
I
54
M
L
T
74
P
L
76
V
L
76
V
L
89
V
I
84
V
I
50
V
L
76
V
L
76
V
MUTATIONS IN THE INTEGRASE GENE ASSOCIATED WITH RESISTANCE TO INTEGRASE INHIBITORS
Raltegravirz
N
155
H
MUTATIONS IN THE ENVELOPE GENE ASSOCIATED WITH RESISTANCE TO ENTRY INHIBITORS 
Enfuvirtidex
Maravirocy
Q
148
H
K
R
E
92
Q
Y
143
R
H
C
G
36
D
S
V
38
A
M
E
Q
39
R
Q
40
H
N
42
T
N
43
D
I
37
V
See User Note
90 54
L
M
100
L
  I*
Amino acid, wild-type
Amino acid position
Amino acid substitution
conferring resistance
Minor (lightface type;
protease only)p
Insertion
MUTATIONS
Amino acid abbreviations: A, alanine; C, cysteine; D, aspartate; 
E, glutamate; F, phenylalanine; G, glycine; H, histidine; 
I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; 
P, proline; Q, glutamine; R, arginine; S, serine; T, threonine;
V, valine; W, tryptophan; Y, tyrosine.

AsterisknMajor (boldface type;
protease only)p
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User Notes
a. Some nucleoside (or nucleotide) analogue 
reverse transcriptase inhibitor (nRTI) muta-
tions, like T215Y and H208Y,1 may lead to 
viral hypersusceptibility to the nonnucleo-
side analogue reverse transcriptase inhibitors 
(NNRTIs), including etravirine,2 in nRTI-treated 
individuals. The presence of these mutations 
may improve subsequent virologic response 
to NNRTI-containing regimens (nevirapine 
or efavirenz) in NNRTI-naive individuals,3-7 
although no clinical data exist for improved 
response to etravirine in NNRTI-experienced 
individuals.
b. The 69 insertion complex consists of a sub-
stitution at codon 69 (typically T69S) and an 
insertion of 2 or more amino acids (S-S, S-A, 
S-G, or others). The 69 insertion complex is as-
sociated with resistance to all nRTIs currently 
approved by the US FDA when present with 1 
or more thymidine analogue–associated muta-
tions (TAMs) at codons 41, 210, or 215.8 Some 
other amino acid changes from the wild-type 
T at codon 69 without the insertion may be as-
sociated with broad nRTI resistance.
c. Tenofovir retains activity against the Q151M 
complex of mutations.8
d. Mutations known to be selected by thymi-
dine analogues (M41L, D67N, K70R, L210W, 
T215Y/F, and K219Q/E, termed TAMs) also 
confer reduced susceptibility to all approved 
nRTIs.9 The degree to which cross-resistance 
is observed depends on the specific muta-
tions and number of mutations involved.10-13 
Mutations at the C-terminal reverse transcrip-
tase domains (amino acids 293-560) outside 
of regions depicted on the figure bars may 
prove to be important for HIV-1 drug resis-
tance. However, to date clinical relevance of 
these in vitro findings has not been estab-
lished14 because the connection domain mu-
tations arise mostly in conjunction with TAMs 
and M184V and do not seem to have major 
independent effects.15
e. Although reverse transcriptase changes as-
sociated with the E44D and V118I mutations 
may have an accessory role in increased resis-
tance to nRTIs in the presence of TAMs, their 
clinical relevance is very limited.16-18
f. The M184V mutation alone does not ap-
pear to be associated with a reduced virologic 
response to abacavir in vivo.19,20 When asso-
ciated with TAMs, M184V increases abacavir 
resistance.19,20 
g. As with tenofovir, the K65R mutation may 
be selected by didanosine, abacavir, or stavu-
dine (particularly in patients with nonsubtype-B 
clades) and is associated with decreased viral 
susceptibility to these drugs.19,21,22 Data are 
lacking on the potential negative impact of 
K65R on clinical response to didanosine.
h. The presence of 3 of the following mutations—
M41L, D67N, L210W, T215Y/F, K219Q/E—is as-
sociated with resistance to didanosine.23 The 
presence of K70R or M184V alone does not 
decrease virologic response to didanosine.24 
i. K65R is selected frequently (4%−11%) in 
patients with nonsubtype-B clades for whom 
stavudine-containing regimens are failing in 
the absence of tenofovir.25,26
j. The presence of M184V appears to delay or 
prevent emergence of TAMs.27 This effect may 
be overcome by an accumulation of TAMs or 
other mutations.
k. The T215A/C/D/E/G/H/I/L/N/S/V substitu-
tions are revertant mutations at codon 215 
that confer increased risk of virologic failure of 
zidovudine or stavudine in antiretroviral-naive 
patients.28-30 The T215Y mutant may emerge 
quickly from 1 of these mutations in the pres-
ence of zidovudine or stavudine.31,32
l. The presence of K65R is associated with a 
reduced virologic response to tenofovir.8 A re-
duced response also occurs in the presence of 
3 or more TAMs inclusive of either M41L or 
L210W.8 The presence of TAMs or combined 
treatment with zidovudine prevents the emer-
gence of K65R in the presence of tenofovir.33-35
m. The sequential use of nevirapine and efavi-
renz (in either order) is not recommended be-
cause of cross-resistance between these drugs.36
n. Resistance to etravirine has been extensively 
studied only in the context of coadministration 
with darunavir/ritonavir. In this context, muta-
tions associated with virologic outcome have 
been assessed and their relative weights (or 
magnitudes of impact) assigned. In addition, 
phenotypic cutoff values have been calculated, 
and assessment of genotype-phenotype corre-
lations from a large clinical database have deter-
mined relative importance of the various muta-
tions. These 2 approaches are in agreement for 
many, but not all, mutations and weights.37-39 
The single mutations Y181C*/I*/V*, K101P*, 
and L100I* reduce but do not preclude clini-
cal utility. Asterisks are used to emphasize their 
higher relative weights with regard to reduced 
susceptibility and reduced clinical response 
when compared with the other etravirine mu-
tations.40 The presence of K103N alone does 
not affect etravirine response.41 Accumulation 
of several mutations results in greater reduc-
tions in susceptibility and virologic response 
than do single mutations.42,43 
o. Often, numerous mutations are necessary 
to substantially impact virologic response to a 
ritonavir-boosted protease inhibitor (PI).44 In 
some specific circumstances, atazanavir might 
be used unboosted. In such cases, the muta-
tions that are selected are the same as with 
ritonavir-boosted atazanavir, but the relative 
frequency of mutations may differ.
p. Resistance mutations in the protease gene 
are classified as “major” or “minor.”
Major mutations in the protease gene 
are defined as those selected first in the 
presence of the drug or those substan-
tially reducing drug susceptibility. These 
mutations tend to be the primary contact 
residues for drug binding. 
Minor mutations generally emerge 
later than major mutations and by them-
selves do not have a substantial effect on 
phenotype. They may improve replica-
tion of viruses containing major muta-
tions. Some minor mutations are pres-
ent as common polymorphic changes in 
HIV-1 nonsubtype-B clades.
q. Ritonavir is not listed separately, as it is 
currently used only at low dose as a pharma-
cologic booster of other PIs. 
r. Many mutations are associated with ata-
zanavir resistance. Their impacts differ, with 
I50L, I84V, and N88S having the greatest ef-
fect. Higher atazanavir levels obtained with 
ritonavir boosting increase the number of 
mutations required for loss of activity. The 
presence of M46I plus L76V might increase 
susceptibility to atazanavir when no other re-
lated mutations are present.45
s. HIV-1 RNA response to ritonavir-boosted 
darunavir correlates with baseline suscepti-
bility and the presence of several specific PI 
mutations. Reductions in response are asso-
ciated with increasing numbers of the muta-
tions indicated in the figure bar. The negative 
impact of the protease mutations I47V, I54M, 
T74P, and I84V and the positive impact of 
the protease mutation V82A on virologic re-
sponse to darunavir/ritonavir were shown in 
2 data sets independently.46,47 Some of these 
mutations appear to have a greater effect on 
susceptibility than others (eg, I50V vs V11I). 
A median darunavir phenotypic fold-change 
greater than 10 (low clinical cutoff) occurs 
with 3 or more of the 2007 IAS–USA muta-
tions listed for darunavir48 and is associated 
with a diminished virologic response.49 
t. The mutations depicted on the figure bar 
cannot be considered comprehensive be-
cause little relevant research has been report-
ed in recent years to update the resistance 
and cross-resistance patterns for this drug. 
u. In PI-experienced patients, the accumula-
tion of 6 or more of the mutations indicated 
on the figure bar is associated with a reduced 
virologic response to lopinavir/ritonavir.50,51 
The product information states that accumu-
lation of 7 or 8 mutations confers resistance 
to the drug.52 However, there is emerging evi-
dence that specific mutations, most notably 
I47A (and possibly I47V) and V32I, are asso-
ciated with high-level resistance.53-55 The ad-
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dition of L76V to 3 PI resistance–associated 
mutations substantially increases resistance 
to lopinavir/ritonavir.45 
v. In some nonsubtype-B HIV-1, D30N is select-
ed less frequently than are other PI mutations.56
w. Clinical correlates of resistance to tip-
ranavir are limited by the paucity of clinical 
trials and observational studies of the drug. 
The available genotypic scores have not been 
validated on large, diverse patient popula-
tions. The presence of mutations L24I, I50L/V, 
F53Y/L/W, I54L, and L76V have been associ-
ated with improved virologic response to tip-
ranavir in some studies.57-59
x. Resistance to enfuvirtide is associated pri-
marily with mutations in the first heptad re-
peat (HR1) region of the gp41 envelope gene. 
However, mutations or polymorphisms in 
other regions of the envelope (eg, the HR2 
region or those yet to be identified) as well 
as coreceptor usage and density may affect 
susceptibility to enfuvirtide.60-62 
y. The activity of CC chemokine receptor 5 
(CCR5) antagonists is limited to patients with 
virus that uses only CCR5 for entry (R5 virus). 
Viruses that use both CCR5 and CXC chemo-
kine receptor 4 (CXCR4; termed dual/mixed 
[D/M]) or only CXCR4 (X4 virus) do not re-
spond to treatment with CCR5 antagonists. 
Virologic failure of these drugs frequently is 
associated with outgrowth of D/M or X4 vi-
rus from a preexisting minority population 
present at levels below the limit of assay de-
tection. Mutations in HIV-1 gp120 that allow 
the virus to bind to the drug-bound form of 
CCR5 have been described in viruses from 
some patients whose virus remained R5 after 
virologic failure of a CCR5 antagonist. Most 
of these mutations are found in the V3 loop, 
the major determinant of viral tropism. There 
is as yet no consensus on specific signature 
mutations for CCR5 antagonist resistance, 
so they are not depicted in the figure. Some 
CCR5 antagonist-resistant viruses selected in 
vitro have shown mutations in gp41 without 
mutations in V3; the clinical significance of 
such mutations is not yet known.
z. Raltegravir failure is associated with inte-
grase mutations in at least 3 distinct genetic 
pathways defined by 2 or more mutations 
including (1) a signature (major) mutation at 
Q148H/K/R, N155H, or Y143R/H/C; and (2) 
1 or more additional minor mutations. Mi-
nor mutations described in the Q148H/K/R 
pathway include L74M plus E138A, E138K, 
or G140S. The most common mutational pat-
tern in this pathway is Q148H plus G140S, 
which also confers the greatest loss of drug 
susceptibility. Mutations described in the 
N155H pathway include this major mutation 
plus either L74M, E92Q, T97A, E92Q plus 
T97A, Y143H, G163K/R, V151I, or D232N.63 
The Y143R/H/C mutation is uncommon.64-68 
Another major mutation, E92Q, has also 
been described.69-71
References to the User Notes
1. Clark SA, Shulman NS, Bosch RJ, Mellors 
JW. Reverse transcriptase mutations 118I, 
208Y, and 215Y cause HIV-1 hypersuscepti-
bility to non-nucleoside reverse transcriptase 
inhibitors. AIDS. 2006;20:981-984.
2. Picchio G, Vingerhoets J, Parkin N, Azijn H, 
de Bethune MP. Nucleoside-associated muta-
tions cause hypersusceptibility to etravirine. 
[Abstract 23.] Antivir Ther. 2008;13(Suppl 
3):A25.
3. Shulman NS, Bosch RJ, Mellors JW, Al-
brecht MA, Katzenstein DA. Genetic corre-
lates of efavirenz hypersusceptibility. AIDS. 
2004;18:1781-1785.
4. Demeter LM, DeGruttola V, Lustgarten 
S, et al. Association of efavirenz hypersus-
ceptibility with virologic response in ACTG 
368, a randomized trial of abacavir (ABC) in 
combination with efavirenz (EFV) and indina-
vir (IDV) in HIV-infected subjects with prior 
nucleoside analog experience. HIV Clin Trials. 
2008;9:11-25.
5. Haubrich RH, Kemper CA, Hellmann NS, 
et al. The clinical relevance of nonnucleoside 
reverse transcriptase inhibitor hypersuscep-
tibility: a prospective cohort analysis. AIDS. 
2002;16:F33-F40.
6. Tozzi V, Zaccarelli M, Narciso P, et al. Muta-
tions in HIV-1 reverse transcriptase potential-
ly associated with hypersusceptibility to non-
nucleoside reverse-transcriptase inhibitors: 
effect on response to efavirenz-based therapy 
in an urban observational cohort. J Infect Dis. 
2004;189:1688-1695.
7. Katzenstein DA, Bosch RJ, Hellmann N, et 
al. Phenotypic susceptibility and virological 
outcome in nucleoside-experienced patients 
receiving three or four antiretroviral drugs. 
AIDS. 2003;17:821-830.
8. Miller MD, Margot N, Lu B, et al. Genotypic 
and phenotypic predictors of the magnitude 
of response to tenofovir disoproxil fumarate 
treatment in antiretroviral-experienced pa-
tients. J Infect Dis. 2004;189:837-846.
9. Whitcomb JM, Parkin NT, Chappey C, Hell-
man NS, Petropoulos CJ. Broad nucleoside re-
verse-transcriptase inhibitor cross-resistance 
in human immunodeficiency virus type 1 clini-
cal isolates. J Infect Dis. 2003;188:992-1000.
10. Larder BA, Kemp SD. Multiple mutations 
in HIV-1 reverse transcriptase confer high-
level resistance to zidovudine (AZT). Science. 
1989;246:1155-1158.
11. Kellam P, Boucher CA, Larder BA. Fifth 
mutation in human immunodeficiency vi-
rus type 1 reverse transcriptase contrib-
utes to the development of high-level resis-
tance to zidovudine. Proc Natl Acad Sci USA. 
1992;89:1934-1938.
12. Calvez V, Costagliola D, Descamps D, et 
al. Impact of stavudine phenotype and thymi-
dine analogues mutations on viral response 
to stavudine plus lamivudine in ALTIS 2 ANRS 
trial. Antivir Ther. 2002;7:211-218.
13. Kuritzkes DR, Bassett RL, Hazelwood 
JD, et al. Rate of thymidine analogue resis-
tance mutation accumulation with zidovu-
dine- or stavudine-based regimens. JAIDS. 
2004;36:600-603.
14. von Wyl V, Ehteshami M, Demeter LM, 
et al. HIV-1 reverse transcriptase connec-
tion domain mutations: dynamics of emer-
gence and implications for success of com-
bination antiretroviral therapy. Clin Infect Dis. 
2010;51:620-628.
15. von Wyl V, Ehteshami M, Symons J, et al. 
Epidemiological and biological evidence for a 
compensatory effect of connection domain mu-
tation N348I on M184V in HIV-1 reverse tran-
scriptase. J Infect Dis. 2010;201:1054-1062.
16. Romano L, Venturi G, Bloor S, et al. Broad 
nucleoside-analogue resistance implications 
for human immunodeficiency virus type 1 
reverse-transcriptase mutations at codons 44 
and 118. J Infect Dis. 2002;185:898-904.
17. Walter H, Schmidt B, Werwein M, 
Schwingel E, Korn K. Prediction of abacavir 
resistance from genotypic data: impact of zi-
dovudine and lamivudine resistance in vitro 
and in vivo. Antimicrob Agents Chemother. 
2002;46:89-94.
18. Mihailidis C, Dunn D, Pillay D, Pozniak 
A. Effect of isolated V118I mutation in reverse 
transcriptase on response to first-line antiret-
roviral therapy. AIDS. 2008;22:427-430.
19. Harrigan PR, Stone C, Griffin P, et al. 
Resistance profile of the human immuno-
deficiency virus type 1 reverse transcriptase 
inhibitor abacavir (1592U89) after monother-
apy and combination therapy. CNA2001 Inves-
tigative Group. J Infect Dis. 2000;181:912-920.
20. Lanier ER, Ait-Khaled M, Scott J, et al. 
Antiviral efficacy of abacavir in antiretroviral 
therapy-experienced adults harbouring HIV-1 
with specific patterns of resistance to nucleo-
side reverse transcriptase inhibitors. Antivir 
Ther. 2004;9:37-45.
21. Winters MA, Shafer RW, Jellinger RA, 
Mamtora G, Gingeras T, Merigan TC. Human 
immunodeficiency virus type 1 reverse tran-
scriptase genotype and drug susceptibility 
changes in infected individuals receiving di-
International AIDS Society–USA        Topics in HIV Medicine
162
deoxyinosine monotherapy for 1 to 2 years. 
Antimicrob Agents Chemother. 1997;41:757-762.
22. Svarovskaia ES, Margot NA, Bae AS, et 
al. Low-level K65R mutation in HIV-1 reverse 
transcriptase of treatment-experienced pa-
tients exposed to abacavir or didanosine. 
JAIDS. 2007;46:174-180.
23. Marcelin AG, Flandre P, Pavie J, et al. 
Clinically relevant genotype interpretation of 
resistance to didanosine. Antimicrob Agents 
Chemother. 2005;49:1739-1744.
24. Molina JM, Marcelin AG, Pavie J, et al. 
Didanosine in HIV-1-infected patients experi-
encing failure of antiretroviral therapy: a ran-
domized placebo-controlled trial. J Infect Dis. 
2005;191:840-847.
25. Hawkins CA, Chaplin B, Idoko J, et al. 
Clinical and genotypic findings in HIV-in-
fected patients with the K65R mutation fail-
ing first-line antiretroviral therapy in Nigeria. 
JAIDS. 2009;52:228-234.
26. Wallis CL, Mellors JW, Venter WD, Sanne 
I, Stevens W. Varied patterns of HIV-1 drug re-
sistance on failing first-line antiretroviral ther-
apy in South Africa. JAIDS. 2010;53:480-484.
27. Kuritzkes DR, Quinn JB, Benoit SL, et 
al. Drug resistance and virologic response in 
NUCA 3001, a randomized trial of lamivudine 
versus zidovudine versus zidovudine plus la-
mivudine in previously untreated patients. 
AIDS. 1996;10:975-981.
28. Riva C, Violin M, Cozzi-Lepri A, et al. 
Transmitted virus with substitutions at posi-
tion 215 and risk of virological failure in anti-
retroviral-naive patients starting highly active 
antiretroviral therapy. [Abstract 124.] Antivir 
Ther. 2002;7:S103.
29. Chappey C, Wrin T, Deeks S, Petropou-
los CJ. Evolution of amino acid 215 in HIV-1 
reverse transcriptase in response to inter-
mittent drug selection. [Abstract 32.] Antivir 
Ther. 2003;8:S37.
30. Violin M, Cozzi-Lepri A, Velleca R, et al. 
Risk of failure in patients with 215 HIV-1 re-
vertants starting their first thymidine analog-
containing highly active antiretroviral thera-
py. AIDS. 2004;18:227-235.
31. Garcia-Lerma JG, MacInnes H, Bennett D, 
Weinstock H, Heneine W. Transmitted human 
immunodeficiency virus type 1 carrying the 
D67N or K219Q/E mutation evolves rapidly 
to zidovudine resistance in vitro and shows 
a high replicative fitness in the presence of 
zidovudine. J Virol. 2004;78:7545-7552.
32. Lanier ER, Ait-Khaled M, Craig C, Scott 
J, Vavro C. Effect of baseline 215D/C/S ‘re-
vertant’ mutations on virological response 
to lamivudine/zidovudine-containing regi-
mens and emergence of 215Y upon viro-
logical failure. [Abstract 146.] Antivir Ther. 
2002;7:S120.
33. Parikh UM, Zelina S, Sluis-Cremer N, Mel-
lors JW. Molecular mechanisms of bidirection-
al antagonism between K65R and thymidine 
analog mutations in HIV-1 reverse transcrip-
tase. AIDS. 2007;21:1405-1414.
34. Parikh UM, Barnas DC, Faruki H, Mellors 
JW. Antagonism between the HIV-1 reverse-
transcriptase mutation K65R and thymidine-
analogue mutations at the genomic level. J 
Infect Dis. 2006;194:651-660.
35. von Wyl V, Yerly S, Boni J, et al. Factors 
associated with the emergence of K65R in 
patients with HIV-1 infection treated with 
combination antiretroviral therapy containing 
tenofovir. Clin Infect Dis. 2008;46:1299-1309.
36. Antinori A, Zaccarelli M, Cingolani A, et 
al. Cross-resistance among nonnucleoside re-
verse transcriptase inhibitors limits recycling 
efavirenz after nevirapine failure. AIDS Res 
Hum Retroviruses. 2002;18:835-838.
37. Benhamida J, Chappey C, Coakley E, Par-
kin NT. HIV-1 genotype algorithms for predic-
tion of etravirine susceptibility: novel muta-
tions and weighting factors identified through 
correlations to phenotype. [Abstract 130.] 
Antivir Ther. 2008;13(Suppl 3):A142.
38. Coakley E, Chappey C, Benhamida J, 
et al. Biological and clinical cut-off analyses 
for etravirine in the PhenoSense HIV assay. 
[Abstract 122.] Antivir Ther. 2008;13(Suppl 
3):A134.
39. Peeters M, Nijs S, Vingerhoets J, et al. 
Determination of phenotypic clinical cut-offs 
for etravirine: pooled week 24 results of the 
DUET-1 and DUET-2 trials. [Abstract 121.] An-
tivir Ther. 2008;13(Suppl 3):A133.
40. Haddad M, Stawiski E, Benhamida J, 
Coakley E. Improved genotypic algorithm for 
predicting etravirine susceptibility: Compre-
hensive list of mutations identified through 
correlation with matched phenotype. [Ab-
stract 574.] 17th Conference on Retroviruses 
and Opportunistic Infections (CROI). Febru-
ary 16-19, 2010; San Francisco, CA.
41. Etravirine [package insert]. Bridgewater, 
NJ: Tibotec Therapeutics; 2008.
42. Vingerhoets J, Peeters M, Azijn H, et al. 
An update of the list of NNRTI mutations asso-
ciated with decreased virological response to 
etravirine: multivariate analyses on the pooled 
DUET-1 and DUET-2 clinical trial data. [Ab-
stract 24.] Antivir Ther. 2008;13(Suppl 3):A26.
43. Scherrer AU, Hasse B, von Wyl V, et al. 
Prevalence of etravirine mutations and im-
pact on response to treatment in routine clini-
cal care: the Swiss HIV Cohort Study (SHCS). 
HIV Med. 2009;10:647-656.
44. Hirsch MS, Günthard HF, Schapiro JM, 
et al. Antiretroviral drug resistance testing 
in adult HIV-1 infection: 2008 recommenda-
tions of an International AIDS Society–USA 
panel. Clin Infect Dis. 2008;47:266-285.
45. Norton M, Young T, Parkin N, et al. Preva-
lence, mutational patterns, and phenotypic 
correlates of the L76V protease mutation in 
relation to LPV-associated mutations. [Ab-
stract 854.] 15th Conference on Retroviruses 
and Opportunistic Infections (CROI). Febru-
ary 3-6, 2008; Boston, MA.
46. De Meyer S, Descamps D, Van Baelen 
B, et al. Confirmation of the negative impact 
of protease mutations I47V, I54M, T74P and 
I84V and the positive impact of protease mu-
tation V82A on virological response to da-
runavir/ritonavir. [Abstract 126.] Antivir Ther. 
2009;14(Suppl 1):A147.
47. Descamps D, Lambert-Niclot S, Mar-
celin AG, et al. Mutations associated with 
virological response to darunavir/ritonavir 
in HIV-1-infected protease inhibitor-expe-
rienced patients. J Antimicrob Chemother. 
2009;63:585-592.
48. Johnson VA, Brun-Vézinet F, Clotet B, et 
al. Update of the drug resistance mutations in 
HIV-1: 2007. Top HIV Med. 2007;15:119-125.
49. De Meyer S, Dierynck I, Lathouwers E, et 
al. Phenotypic and genotypic determinants of 
resistance to darunavir: analysis of data from 
treatment-experienced patients in POWER 1, 
2, 3 and DUET-1 and 2. [Abstract 31.] Antivir 
Ther. 2008;13(Suppl 3):A33.
50. Masquelier B, Breilh D, Neau D, et al. 
Human immunodeficiency virus type 1 ge-
notypic and pharmacokinetic determinants 
of the virological response to lopinavir-ritona-
vir-containing therapy in protease inhibitor-
experienced patients. Antimicrob Agents Che-
mother. 2002;46:2926-2932.
51. Kempf DJ, Isaacson JD, King MS, et al. 
Identification of genotypic changes in human 
immunodeficiency virus protease that cor-
relate with reduced susceptibility to the pro-
tease inhibitor lopinavir among viral isolates 
from protease inhibitor-experienced patients. 
J Virol. 2001;75:7462-7469.
52. Lopinavir/ritonavir [package insert]. Ab-
bott Park, IL: Abbott Laboratories; 2008.
53. Mo H, King MS, King K, Molla A, Brun S, 
Kempf DJ. Selection of resistance in protease 
inhibitor-experienced, human immunodefi-
ciency virus type 1-infected subjects failing 
lopinavir- and ritonavir-based therapy: muta-
tion patterns and baseline correlates. J Virol. 
2005;79:3329-3338.
163
 Special Contribution – December 2010 Resistance Mutations Update   Volume 18 Issue 5   December 2010
54. Friend J, Parkin N, Liegler T, Martin JN, 
Deeks SG. Isolated lopinavir resistance after 
virological rebound of a ritonavir/lopinavir-
based regimen. AIDS. 2004;18:1965-1966.
55. Kagan RM, Shenderovich M, Heseltine 
PN, Ramnarayan K. Structural analysis of 
an HIV-1 protease I47A mutant resistant to 
the protease inhibitor lopinavir. Protein Sci. 
2005;14:1870-1878.
56. Gonzalez LMF, Brindeiro RM, Aguiar RS, 
et al. Impact of nelfinavir resistance muta-
tions on in vitro phenotype, fitness and rep-
lication capacity of HIV-1 with subtype B 
and C proteases. [Abstract 56.] Antivir Ther. 
2004;9:S65.
57. Rhee S-Y, Taylor J, Fessel WJ, et al. HIV-
1 protease mutations and protease inhibitor 
cross-resistance. Antimicrob Agents Chemother. 
2010;54:4253-4261.
58. Schapiro JM, Scherer J, Boucher CA, et 
al. Improving the prediction of virological re-
sponse to tipranavir: the development and 
validation of a tipranavir-weighted mutation 
score. Antivir Ther. 2010;15:1011-1019.
59. Marcelin AG, Masquelier B, Descamps 
D, et al. Tipranavir-ritonavir genotypic re-
sistance score in protease inhibitor-experi-
enced patients. Antimicrob Agents Chemother. 
2008;52:3237-3243.
60. Reeves JD, Gallo SA, Ahmad N, et al. Sen-
sitivity of HIV-1 to entry inhibitors correlates 
with envelope/coreceptor affinity, receptor 
density, and fusion kinetics. Proc Natl Acad Sci 
USA. 2002;99:16249-16254.
61. Reeves JD, Miamidian JL, Biscone MJ, 
et al. Impact of mutations in the coreceptor 
binding site on human immunodeficiency vi-
rus type 1 fusion, infection, and entry inhibi-
tor sensitivity. J Virol. 2004;78:5476-5485.
62. Xu L, Pozniak A, Wildfire A, et al. Emer-
gence and evolution of enfuvirtide resistance 
following long-term therapy involves heptad 
repeat 2 mutations within gp41. Antimicrob 
Agents Chemother. 2005;49:1113-1119.
63. Hazuda DF, Miller MD, Nguyen BY, Zhao 
J, for the P005 Study Team. Resistance to the 
HIV-integrase inhibitor raltegravir: analysis of 
protocol 005, a phase II study in patients with 
triple-class resistant HIV-1 infection. Antivir 
Ther. 2007;12:S10.
64. Miller MD, Danovich RM, Ke Y, et al. Lon-
gitudinal analysis of resistance to the HIV-1 
integrase inhibitor raltegravir: results from 
P005 a phase II study in treatment-experi-
enced patients. [Abstract 6.] Antivir Ther. 
2008;13:A8.
65. Fransen S, Gupta S, Danovich R, et al. 
Loss of raltegravir susceptibility in treated 
patients is conferred by multiple non-overlap-
ping genetic pathways. [Abstract 7.] Antivir 
Ther. 2008;13:A9.
66. Hatano H, Lampiris H, Huang W, et al. 
Virological and immunological outcomes in a 
cohort of patients failing integrase inhibitors. 
[Abstract 10.] Antivir Ther. 2008;13:A12.
67. Da Silva D, Pellegrin I, Anies G, et al. 
Mutational patterns in the HIV-1 integrase 
related to virological failures on raltegravir-
containing regimens. [Abstract 12.] Antivir 
Ther. 2008;13:A14.
68. Ceccherini-Silberstein F, Armenia D, 
D’Arrigo R, et al. Virological response and 
resistance in multi-experienced patients 
treated with raltegravir. [Abstract 18.] Anti-
vir Ther. 2008;13:A20.
69. Cooper DA, Steigbigel RT, Gatell JM, et al. 
Subgroup and resistance analyses of raltegra-
vir for resistant HIV-1 infection. N Engl J Med. 
2008;359:355-365.
70. Malet I, Delelis O, Valantin MA, et al. Mu-
tations associated with failure of raltegravir 
treatment affect integrase sensitivity to the 
inhibitor in vitro. Antimicrob Agents Chemoth-
er. 2008;52:1351-1358.
71. Geretti AM, Fearnhill E, Ceccherini-Silber-
stein F, et al. Prevalence and patterns of ralte-
gravir resistance in treated patients in Europe. 
[Abstract 51.] Antivir Ther. 2010;159(Suppl 
2):A62.
Top HIV Med. 2010;18(5):156-163
©2010, International AIDS Society–USA
